CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to enhance the BCG vaccine for tuberculosis by developing a novel adjuvant using genetically modified lipopolysaccharides from Neisseria meningitidis. The modifications target immune cells to improve the vaccine's effectiveness while reducing toxicity, potentially benefiting various vaccines beyond tu…
Tuberculosis, a disease caused by the bacterium Mycobacterium tuberculosis, kills 2-3 million people per year.
Although an attenuated strain of M.bovis called BCG is widely used as vaccine against TB, its effectiveness is generally considered as insufficient.
Our new approach for BCG improvement is to add a novel type of adjuvant, based on genetically engineered versions of the lipopolysaccharide (LPS) from Neisseria meningitidis (Nm).
The modifications aim at (i) specific targeting to dendritic…
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
MINISTRY OF HEALTH, WELFARE AND SPORT
Netherlands, Den Haag
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
